NAD+ Levels Drop 40-50% After Age 40

NAD+ Drops by 40–50% Between Ages 40 and 60

The fundamental energy currency of every cell, nicotinamide adenine dinucleotide (NAD+), undergoes a steep, tissue-specific decline during aging. In human skin, for example, researchers have documented a 40–50% reduction from age 40 to 60. This loss corresponds with the onset of hallmark aging processes: mitochondrial dysfunction, genomic instability, and epigenetic changes. The scientific pursuit to safely restore NAD+ levels has positioned its precursor molecules, particularly nicotinamide mononucleotide (NMN), at the center of evidence-based longevity research.

A 2026 systematic review by Gallagher and Emmanuel in *Ageing Research Reviews* analyzed 113 rodent and human studies on NAD+ augmentation. It found that while oral NMN and its relative nicotinamide riboside (NR) reliably boost NAD+ metabolites in humans, their effects on functional health outcomes are inconsistent.

Simultaneously, a specific mechanism for how NAD+ decline drives aging has emerged. In *Aging Cell*, a team from the Chinese Academy of Sciences identified a direct link between intestinal NAD+ loss and systemic organ damage.

Aging Intestine Suffers an Energy Crisis, Halting Protective HDL3 Production

Li Y and colleagues at the Tianjin Institute of Industrial Biotechnology discovered that aging disrupts a critical protective axis between the gut and the liver. The intestine not only absorbs nutrients but also synthesizes essential signaling metabolites. One is a specific type of high-density lipoprotein called HDL3.

Mitochondria and ABCA1 Fail Without NAD+

Their study in mice found aging intestinal cells enter an energy crisis. Mitochondria, the cell’s power plants, become inefficient due to NAD+ scarcity. This NAD+ deficiency also impairs the function of a membrane protein called ABCA1, which is responsible for packaging lipids into nascent HDL3 particles. The result is a significant drop in the intestine’s production of HDL3.

Gut-Derived HDL3 Neutralizes Liver Toxins

The research team demonstrated that gut-originated HDL3 plays a non-canonical role. It travels to the liver, where it binds to and neutralizes lipopolysaccharide (LPS), a potent inflammatory toxin that can leak from an aging gut. By mopping up LPS, HDL3 prevents it from triggering a TLR4-mediated inflammatory cascade that leads to liver cell injury and fibrosis. This axis deteriorates with age as HDL3 production falters.

For a detailed examination of this gut-liver mechanism, see our article Intestinal Energy Crisis Triggers Systemic Aging in Gut-Liver Axis.

NMN Reverses the Crisis by Restoring NAD+ and ATP

The intervention part of the study points to a potential therapeutic strategy. Exogenous supplementation with β-nicotinamide mononucleotide (NMN) reversed the observed aging defects in the mouse model.

NMN restored intestinal NAD+ homeostasis. This replenishment enhanced mitochondrial oxidative phosphorylation efficiency, increasing cellular ATP levels. With more energy available, the ABCA1 transporter function improved, restarting the biosynthesis and secretion of gut-derived HDL3. The restored HDL3 flow to the liver subsequently reduced LPS toxicity and attenuated inflammatory signaling, ameliorating age-related liver injury.

“These findings elucidate a novel mechanism whereby NMN modulates the NAD+-mitochondria/ABCA1-HDL3 axis to preserve gut-liver axis function,” the authors concluded. This provides a molecular explanation for how boosting NAD+ could mitigate systemic aging linked to intestinal decline. More on this reversal is covered in Restoring Gut-Liver Axis: NMN Targets Aging Intestinal Energy.

Human Evidence Shows Reliable NAD+ Boosting But Mixed Functional Benefits

The rodent model data are compelling, but human translation is complex. The 2026 systematic review by Gallagher and Emmanuel provides a necessary counterbalance.

Biochemical Efficacy is Clear

Across 28 randomized human trials, oral supplementation with NAD+ precursors like NMN and NR consistently demonstrated “biochemical target engagement.” This means they reliably increased levels of NAD+ and related metabolites in plasma, whole blood, or peripheral blood mononuclear cells. The supplements were generally well-tolerated over periods of weeks to months.

Health Outcome Results are Heterogeneous

However, effects on tangible health and function were less uniform. The review noted “effects on functional, metabolic, vascular, and other healthspan-relevant outcomes were heterogeneous and often null or endpoint-specific.” Some studies reported improvements in vascular elasticity or muscle metabolism, while others found no significant change compared to placebo. The largest, most robust outcomes trials in humans are still awaited.

Furthermore, the review identified a significant gap in evidence for direct intravenous or intramuscular NAD+ administration for anti-aging purposes. The authors could not identify any eligible outcomes trials for this increasingly popular wellness practice, highlighting a disconnect between clinical science and commercial application.

Practical Considerations for NMN Supplementation

For individuals considering NMN supplementation based on the current evidence, several practical factors require attention.

Dosage and Form

Human trials have used a wide range of oral NMN doses, typically from 250 mg to 1000 mg daily. No universal optimal dose has been established, and needs may vary by age and health status. NMN is available in powder and capsule forms; its stability and bioavailability can be influenced by manufacturing and storage conditions.

Combination with Foundational Practices

NAD+ biology does not operate in isolation. The proven, foundational lifestyle interventions that support NAD+ levels and mitochondrial health remain critical. These include regular aerobic and resistance exercise, which acutely stress and strengthen mitochondria, and maintaining a healthy circadian rhythm through consistent sleep schedules and timed eating. Caloric restriction or fasting practices, as explored in our guide Caloric Restriction for Lifespan and Healthspan, are also potent natural stimulators of NAD+ synthesis.

It is reasonable to view NMN as a potential supplement to these core behaviors, not a replacement for them.

Key Takeaways

• NAD+ levels decline substantially with age, contributing to mitochondrial dysfunction and cellular energy deficits.
• Aging disrupts the gut-liver axis via an intestinal energy crisis. Low NAD+ impairs HDL3 production, allowing liver inflammation and damage to proceed.
• In preclinical models, NMN supplementation reverses this defect by restoring NAD+, mitochondrial ATP output, and protective HDL3 synthesis.
• Human trials confirm NMN and NR reliably boost blood NAD+ levels but show mixed and often null results for concrete functional health benefits.
• No robust clinical trial evidence supports intravenous NAD+ for anti-aging, despite its use in wellness clinics.
• Lifestyle factors like exercise and sleep are foundational for maintaining NAD+ metabolism and overall healthspan.
• NMN remains a promising but not yet proven intervention for extending human healthspan; larger, longer-term outcomes trials are needed.

This article is for informational purposes only. Consult a qualified healthcare professional for personalised advice before beginning any new supplement regimen.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41851037/
https://pubmed.ncbi.nlm.nih.gov/41655607/
https://pubmed.ncbi.nlm.nih.gov/41512967/